Stock comparison
Genmab A/S
United Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
UTHR
United Therapeutics
Market cap
$24.13B
Sector
Healthcare
Overall winner
United Therapeutics UTHR
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GMAB | UTHR | Winner |
|---|---|---|---|
| Warren Buffett | 65C | 71B | UTHR |
| Benjamin Graham | 64C | 76B | UTHR |
| Philip Fisher | 48D | 76B | UTHR |
| Peter Lynch | 25F | 62C | UTHR |
| Joel Greenblatt | 76B | 46D | GMAB |
| Charlie Munger | 68C | 64C | GMAB |
| Terry Smith | 71C | 64C | GMAB |
Side-by-side metrics
| Metric | GMAB | UTHR |
|---|---|---|
| Market cap | $16.5B | $24.13B |
| P/E (TTM) | 6.2x | 19.2x |
| EV/EBIT | 12.0x | 15.2x |
| ROIC (TTM) | 43.78% | 18.81% |
| Gross margin | 93.88% | 86.58% |
| Net margin | 18.23% | 40.61% |
| Revenue CAGR 5y | -18.45% | 17.22% |
| EPS CAGR 5y | -23.48% | 29.84% |
| Debt / Equity | 0.1x | - |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GMAB leads on
- P/E (TTM)6.2xvs 19.2x+68%
- ROIC (TTM)43.78%vs 18.81%+57%
- EV/EBIT12.0xvs 15.2x+21%
- Gross margin93.88%vs 86.58%+8%
UTHR leads on
- Revenue CAGR 5y17.22%vs -18.45%+193%
- EPS CAGR 5y29.84%vs -23.48%+179%
- Debt / Equity-vs 0.1x+100%
- Net margin40.61%vs 18.23%+55%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.